Fundraising FoxStork Therapeutics
San Francisco, US · Founded 2024 · Delaware corporation
Find your way into Stork Therapeutics
Sign up to see every warm intro you have to Stork Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Stork Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Stork Therapeutics is developing CAR T cell therapies to expand the potential of that treatment modality.
Founders & leadership
Stork Therapeutics was founded in 2024 by Gregg Fine.
GF
Gregg FineFounder & CEOGregg Fine is a physician-scientist and adult hematologist/oncologist with expertise in tumor immunology and T cell biology who has led multiple cell and gene therapy programs through clinical development and regulatory milestones including IND filings and breakthrough therapy designations. He has held executive leadership roles at biotech companies from early stage through IPO, with experience in CAR T cell therapies, neoantigen cancer vaccines, and gene-edited TCR T cells across solid and liquid tumors.
MB
Michael BethuneHead of Discovery ResearchMichael Bethune held research positions at PACT Pharma, Allogene, and CARGO, where he worked on T cell engineering, CAR-T technologies, and immunotherapy approaches for cancer, with prior published research in immunology and immunotherapy.
NJ
Nayan JainHead of Translational Research
Board
BK
Reported raises · per SEC filings
Form D private placements$1.3M disclosed across 1 round · 2025
▶$1.3MraisedMay 2025 · 3 investors · BiotechnologyRule 506(b)
▶$1.3MraisedMay 2025 · 3 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Brendan KennedyDirector
- Gregg FineExecutive Officer, Director, Promoter
- Offering amount
- $2.7M
- Amount sold
- $1.3M
- First sale
- Apr 2025
- Incorporated
- Corporation, Delaware, 2024
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does Stork Therapeutics do?
- Stork Therapeutics is developing CAR T cell therapies to expand the potential of that treatment modality.
- Who founded Stork Therapeutics?
- Stork Therapeutics was founded by Gregg Fine in 2024.
- How much funding has Stork Therapeutics raised?
- Stork Therapeutics has disclosed $1.3M raised across 1 round.
- Where is Stork Therapeutics headquartered?
- Stork Therapeutics is headquartered in San Francisco, US.